Key Highlights
- Michelle Mellion, M.D. promoted to Chief Medical Officer.
- Hayley Parker, Ph.D. promoted to Senior Vice President, Global Regulatory Affairs.
- Promotions underscore their contributions to clinical and regulatory strategies.
- PepGen aims to advance next-generation oligonucleotide therapies.
Source: Business Wire
Notable Quote
- “I am excited to announce the well-deserved promotions of Michelle and Hayley, a true testament to their hard work, dedication, and leadership. Since joining PepGen, they have played integral roles in driving both our clinical and regulatory strategies, advancing our pipeline of differentiated oligonucleotides, and paving a path for future commercialization.” — James McArthur, Ph.D., President and CEO at PepGen
SoHC's Take
PepGen Inc.’s recent executive promotions highlight the company’s commitment to bolstering its leadership team with experienced professionals crucial for advancing its clinical and regulatory strategies. Michelle Mellion, M.D., with her extensive background in clinical development and neurology, will now steer PepGen’s medical initiatives as Chief Medical Officer. Simultaneously, Hayley Parker, Ph.D., whose expertise in global regulatory affairs is invaluable, will lead the regulatory pathway as Senior Vice President. These strategic promotions are poised to strengthen PepGen’s mission of developing innovative oligonucleotide therapies aimed at transforming the treatment of severe neuromuscular and neurological diseases.
